Sp60
IDENTIFICATION OF DYSPLASIA IN BARRETT'S ESOPHAGUS
Date
May 18, 2024
Presenter
University of North Carolina at Chapel Hill School of Medicine
Tracks
Related Products
IMPACT OF UP TO 6 MONTHS OF MEPOLIZUMAB TREATMENT FOR ADOLESCENTS AND ADULTS WITH EOSINOPHILIC ESOPHAGITIS IN THE SECOND PHASE OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL
BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
QUALITY INDICATORS IN BARRETT'S ESOPHAGUS: READY FOR PRIMETIME?
Barrett's esophagus is the only precancerous condition for esophageal adenocarcinoma; a cancer that is associated with rising incidence and high morbidity and mortality rates…
